The need to curb the emergence and spread of *M. tuberculosis* drug resistance requires exploration of new methods especially in high incidence countries. Effective treatment informed by timely and accurate drug susceptibility testing is critical to control drug-resistant tuberculosis. Next-generation whole-genome sequencing is increasingly becoming attractive and could potentially provide a fast and comprehensive determination of drug susceptibility that could inform timely treatment decisions. The aim of this study is to use next-generation whole-genome sequencing analysis to understand *M. tuberculosis* drug resistance, population structure, and transmission dynamics in Botswana. The study will be a retrospective cross sectional study using isolates from adults diagnosed with drug-resistant pulmonary tuberculosis by culture based drug susceptibility testing at Botswana National Tuberculosis Reference Laboratory in Gaborone, Botswana. A total of 150 isolates with a spectrum of resistance ranging from mono-resistance to multidrug-resistant tuberculosis (MDR-TB) will be selected for next-generation whole-genome sequencing using the Illumina MiSeq^®^ system (Illumina, San Diego, California). FASTQ files or Unmapped Binary Alignment Map (BAM) files of the reads generated will be assembled and aligned using Geneious, Genome Analysis Toolkit (GATK), and SamTools. Alignment output for each sample will then be indexed, sorted, and merged into a single alignment file using SamTools. SNP calling will be done using Genius, GATK, and SamTools; the SNPs detected by at least two methods will be deemed real and compared to a TB drug resistance mutation list (<http://pfgrc.jcvi.org/>). The list includes 1,086 SNPs identified in thirty *M. tuberculosis* genes.
